Tharimmune (THAR) CEO granted 20,000 options at $3.075 on 11/03/2025
Tharimmune (THAR) CEO and director Sireesh Appajosyula reported a stock option grant for 20,000 shares at an exercise price of $3.075 on 11/03/2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Tharimmune (THAR) CEO and director Sireesh Appajosyula reported a stock option grant for 20,000 shares at an exercise price of $3.075 on 11/03/2025.
The options are exercisable on 11/03/2025 and expire on 11/03/2035. Following the grant, the filing lists 225,962 derivative securities beneficially owned, held direct. No non‑derivative transactions were reported in Table I.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 20,000 | $0.00 | $0.00 |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did THAR report on this Form 4?
What is the exercise price and timing for the THAR options?
How many derivative securities does the insider hold after the transaction?
Did the Form 4 report any open market purchases or sales of common stock?
What roles does the reporting person hold at Tharimmune (THAR)?
What is the security underlying the options?
AI-generated analysis. How Rhea-AI works. Not financial advice.